Orion considers $26M Phase III Simdax trial

Finland's Orion Corporation is considering putting up $26 million to fund a new Phase III trial of the heart failure drug Simdax. Orion officials announced that they are in talks with Abbott Laboratories about the further testing of the therapy. Both companies plan discussions with the FDA over the trial, set to begin in March.

- check out this press release for more
- here's the report on Orion from ABC Money

Related Article:
Orion ponders new Phase III for Simdax. Report

Suggested Articles

Novartis is forging ahead with the development of spartalizumab in "many, many other indications" despite the setback.

Chi-Med has detailed plans to seek approval from the FDA later this year in part on the strength of data from Chinese phase 3 trial.

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.